eXmoor Pharma has established a strategic collaboration with the Translational Research Office (TRO) and University College London (UCL) to accelerate cell and gene therapy (CGT) development.
The collaboration aims to streamline the development process of CGTs, from initial academic research to clinical application. It will support engagement between UCL innovators and eXmoor’s experienced multidisciplinary teams. Additionally, it will integrate the TRO’s translational research expertise with eXmoor’s consultancy, development and Good Manufacturing Practice (GMP) capacities.
CGT candidates are often delayed in development by technical and regulatory issues. The collaboration will grant researchers at UCL access to eXmoor’s experts and services, including grant input, regular consultancy clinics and joint events. They will also gain access to GMP manufacturing for early-stage clinical studies.
In exchange, eXmoor will work directly alongside UCL’s researchers, keeping its own teams up to date with the latest CGT modalities.
“UCL is committed to driving innovation that transforms lives, with a world-leading pipeline of Advanced Therapy Medicinal Products (ATMPs),” Pamela Tranter, head of the Translational Research Group at UCL TRO, said.
eXmoor brings over two decades of consultancy experience to its CGT manufacturing and commercialisation capabilities. It acts as a partner for innovators scaling their CGT therapies. The TRO works to translate UCL’s breakthrough biomedical research into real-world applications such as drugs, diagnostics and medical devices.
Angela Osborne, founder and executive chair of eXmoor, commented: “The strength of the UK’s academic science has always been clear, but getting groundbreaking therapies from the lab to patients requires a collaborative approach. This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients.”
